Novartis Buys Rights to Multiple Sclerosis Drug from GlaxoSmithKline

24.08.2015 - Novartis is acquiring all the remaining rights to GlaxoSmithKline’s (GSK) multiple sclerosis (MS) drug, Ofatumumab. A fully human monoclonal antibody which targets the CD20...